Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label dose-escalation BNCT with SPM-011 in recurrent malignant glioma
jRCT2051210053Completed
- Sponsor
- Stella Pharma
- Start
- Nov 2012
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of borofalan in malignant glioma and glioblastoma (GBM) (3 cohorts), sponsored by Stella Pharma. Primary endpoints: Safety and Tolerability. Started Nov 2012; status: completed.
02
Drugs
borofalan
03
Conditions
malignant gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2051210053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210053.